Research Progress of the Treatment of PD-1 Immune CheckpointInhibitors in Oral Squamous Cell Carcinoma

Updata:01-01-1970

Source:
By:Author(s)

DOI: https://doi.org/10.30564/jor.v2i2.2429

Abstract:
Targeted immune checkpoint-based immunotherapy has achieved remarkable success in the treatment of malignant tumors. Immune checkpoint inhibitor-programmed cell death protein 1 (PD-1) antibody opens a new era of immunotherapy for platinum-refractory recurrent/metastatic oral squamous cell carcinoma (OSCC). The overall survival of patients treated with immunological checkpoint inhibitors was significantly prolonged, and the overall incidence of grade 3-4 drug-related adverse events (AEs) occurred was lower; however, there are still some challenges to the PD-1’s application in OSCC clinic treatment. This article is just to briefly highlight the development of such application to date.
References:

[1]Sievilainen M, Almahmoudi R, Al-Samadi A, Salo T, Pirinen M, Almangush A. The prognostic value of immune checkpoints in oral squamous cell carcinoma. Oral diseases, 2018. DOI: 10.1111/odi.12991 [2]Chen Y, Li Q, Li X, et al. Blockade of PD-1 effectively inhibits in vivo malignant transformation of oral mucosa. Oncoimmunology, 2018, 7(2): e1388484. DOI: 10.1080/2162402X.2017.1388484. eCollection 2018 [3]Jiang C, Yuan F, Wang J, Wu L. Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages. Immunobiology, 2017, 222(4): 651-7. DOI: 10.1016/j.imbio.2016.12.002. Epub 2016 Dec 14 [4]Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral oncology, 2009, 45(4-5): 309-16. DOI: 10.1016/j.oraloncology.2008.06.002. Epub 2008 Sep 18 [5]Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008, 26:677-704.DOI: 10.1146/annurev.immunol.26.021607.090331 [6]Cho YA, Yoon HJ, Lee JI, Hong SP, Hong SD. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral oncology, 2011, 47(12): 1148-53. DOI: 10.1016/j.oraloncology.2011.08.007. Epub 2011 Sep 10 [7]Tsushima F, Tanaka K, Otsuki N, et al. Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral oncology, 2006, 42(3): 268-74. DOI: 10.1016/j.oraloncology.2005.07.013. Epub 2005 Nov 3 [8]Zheng P, Zhou Z. Human cancer immunotherapy with PD-1/PDL1blockade [J]. Biomark Cancer, 2015, 7(Suppl 2): 15-18. DOI: 10.4137/BIC.S29325 [9]Yearley JH, Gibson C, Yu N, et al. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clinical cancer research: an official journal of the American Association for Cancer Research, 2017, 23(12): 3158-67. DOI: 10.1158/1078-0432.CCR-16-1761 [10]Mandal R, Senbabaoglu Y, Desrichard A, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI insight, 2016, 1(17): e89829. DOI: 10.1172/jci.insight.89829 [11]Kansy BA, Concha-Benavente F, Srivastava RM, et al. PD-1 Status in CD8(+) T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. Cancer research, 2017, 77(22): 6353-64. DOI: 10.1158/0008-5472.CAN-16-3167. Epub 2017 Sep 13 [12]Mattox AK, Lee J, Westra WH, et al. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4(+) TILs in the Presence of PD-L1(+) TAMs. Cancer research, 2017, 77(22): 6365-74. DOI: 10.1158/0008-5472.CAN-16-3453. Epub 2017 Sep 25 [13]Zhang P, Ouyang S, Wang J, et al. Levels of programmed death-1 and programmed death ligand-1 in the peripheral blood of patients with oral squamous cell carcinoma and its clinical implications. West China journal of stomatology, 2015, 33(5): 529-33. URL:http://www.ncbi.nlm.nih.gov/pubmed/26688950 [14]Malaspina TS, Gasparoto TH, Costa MR, et al. Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma. Cancer immunology, immunotherapy: CII 2011, 60(7): 965-74. DOI: 10.1007/s00262-011-1007-5. Epub 2011 Mar 27 [15]Weber M, Wehrhan F, Baran C, et al. PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma. Oncotarget, 2017, 8(68): 112584-97. DOI: 10.18632/oncotarget.22576. eCollection 2017 Dec 22 [16] Ferris RL, Blumenschein G, Jr., Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. The New England journal of medicine, 2016, 375(19): 1856-67. DOI: 10.1016/j.oraloncology.2018.04.008. Epub 2018 Apr 17 [16]de Vicente JC, Rodriguez-Santamarta T, Rodrigo JP, Blanco-Lorenzo V, Allonca E, Garcia-Pedrero JM. PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2019, 28(3): 546-54. DOI: 10.1158/1055-9965.EPI-18-0779. Epub 2018 Nov 28 [17]Fusi A, Festino L, Botti G, et al. PD-L1 expression as a potential predictive biomarker. The Lancet Oncology, 2015, 16(13): 1285-7. DOI: 10.1016/S1470-2045(15)00307-1 [19] Polverini PJ, D’Silva NJ, Lei YL. Precision Therapy of Head and Neck Squamous Cell Carcinoma. Journal of dental research, 2018, 97(6): 614-21. DOI: 10.1177/0022034518769645. Epub 2018 Apr 12 [20]Rexer H. [Study on therapy of metastasized or locally advanced urothelial cancer: A phase III randomized clinical trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel or vinflunine in subjects with recurrent or progressive metastatic urothelial cancer (Keynote 045) - AP 48/15 der AUO]. Der Urologe Ausg A, 2015; 54(9): 1287-90. DOI: 10.1007/s00120-015-3934-9 [21]Burtness B, Harrington KJ, Greil R et al. KEYNOTE-048: phase 3 study of first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). ESMO Meeting, 2018. [22]Ferris RL, Blumenschein G, Jr., Fayette J, et al. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head andneck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral oncology, 2018, 81: 45-51. DOI: 10.1016/j.oraloncology.2018.04.008. Epub 2018 Apr 17 [23]Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T, Konishi I. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol., 2016, 21: 462-473. DOI: 10.1007/s10147-016-0959-z [24]Segal NH. Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. J Clin Oncol., ASCO meeting abstracts, 2015, 33(Suppl): abstr 3011. [25]Chervin CS, Brockstein B. Current clinical immunotherapeutic approaches for head and neck cancer. F1000Res. Epub 2016 May 5. DOI: 10.12688/f1000research.7762.1 [26]Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (Lond), 2014, 515: 563-567. DOI: 10.1038%2Fnature14011 [27]Hang W, Xu ZX, Zhang Q, Lu X, Liu G. [Immune checkpoint inhibitor therapy in advanced head and neck cancer]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017;52(1):67-70. (In Chinese) DOI: 10.3760/cma. j. issn.1673-0860.2017.01.015 [28] Argiris A, Harrington KJ, Tahara M, et al. Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Front Oncol., 2017, 7: 72. DOI: 10.3389/fonc.2017.00072 [29] Saleh K, Eid R, Haddad FG, Khalife-Saleh N, Kourie HR. New developments in the management of head and neck cancer - impact of pembrolizumab. Therapeutics and clinical risk management, 2018, 14: 295-303. DOI: 10.2147/TCRM. S125059 [30]Wise-Draper TM, Old MO, Worden FP, et al. Phase II multi-site investigation of neoadjuvant pembrolizumab and adjuvant concurrent radiation and pembrolizumab with or without cisplatin in resected head and neck squamous cell carcinoma. J Clin Oncol. 2018, 36(suppl): abstr 6017. [31]Uppaluri R, Zolkind P, Lin T, et al. Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma. (HNSCC). J Clin Oncol., 2017, 15(suppl): 6012. DOI: 10.1200/JCO.2017.35.15_suppl.6012 [32]Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England journal of medicine, 2012, 366(26): 2443-54. DOI: 10.1056/NEJMoa1200690 [33]O’Donnell JS, Long GV, Scolyer RA, Teng MW, Smyth MJ. Resistance to PD1/PDL1 checkpoint inhibition. Cancer treatment reviews, 2017, 52: 71-81. DOI: 10.1016/j. ctrv.2016.11.007 [34]Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Science translational medicine, 2016, 8(328): 328rv4. DOI: 10.1126/scitranslmed. aad7118 [35]Rafiq S, Yeku OO, Jackson HJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nature biotechnology, 2018, 36(9): 847-56. DOI: 10.1038/nbt.4195 [36]Economopoulou P, Perisanidis C, Giotakis EI, Psyrri A. The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications. Annals of translational medicine, 2016, 4(9): 173. DOI: 10.21037/atm.2016.03.34 [37]Pan D, Kobayashi A, Jiang P, et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science, 2018, 359(6377): 770-5. DOI: 10.1126/science. aao1710 [38]Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science, 2018, 359(6377): 801-6. DOI: 10.1126/science. aan5951 [39] Guerrero-Preston R, White JR, Godoy-Vitorino F et al. High-resolution microbiome profiling and genome wide arrays uncover bacteria driven alterations of oncogenic and immune pathways in head and neck cancer patients treated with surgery, chemo-radiation and PD-1 checkpoint blockade therapy. Cancer Resh, 2017, 77(Suppl 13): 1018-1018.

Tags: